ERBB2 amplification

About

Gene context: ERBB2

Biomarker Type: Copy Number

Present: True

Direction: Amplification


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (3) ERBB2 amplification Invasive Breast Carcinoma Docetaxel, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ERBB2 amplification Non-Small Cell Lung Cancer Trastuzumab deruxtecan
EMA (1) ERBB2 amplification Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan
EMA (2) ERBB2 amplification Invasive Breast Carcinoma Trastuzumab
EMA (2) ERBB2 amplification Invasive Breast Carcinoma Paclitaxel, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Doxorubicin, Paclitaxel, Trastuzumab
EMA (1) ERBB2 amplification Esophagogastric Adenocarcinoma Capecitabine, Cisplatin, Trastuzumab
EMA (1) ERBB2 amplification Esophagogastric Adenocarcinoma Cisplatin, Fluorouracil, Trastuzumab
EMA (2) ERBB2 amplification Invasive Breast Carcinoma Trastuzumab emtansine
EMA (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) ER positive, ERBB2 amplification Invasive Breast Carcinoma Neratinib
EMA (1) ERBB2 amplification, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Capecitabine, Lapatinib
EMA (1) ER positive, ERBB2 amplification, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab
EMA (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole